Non-Standard Therapies Used in 20% of Localized High-Risk PCa Cases
Using EBRT alone or ADT alone for high-risk localized prostate cancer is associated with worse survival outcomes.
Race Differences
Black Race Not Associated With Higher Prostate Cancer Death Risk
Investigators propose that nonbiological factors account for differences in prostate cancer-specific mortality between black and white men.
Black PCa Patients Opt Less for Active Surveillance, Watchful Waiting
In 2015, black men were 16% less likely than nonblack men to choose active surveillance or watchful waiting for low-risk prostate cancer.
Testicular Cancer More Life Threatening in Blacks
The 10-year mortality risk from testicular cancer is 12% higher among black men compared with white men.
PCa Genomic Test May Predict Outcomes More Accurately in African-American Men
The Decipher genomic classifier predicted metastases and prostate cancer-specific mortality following radical prostatectomy with greater precision in African-American men.
Newer mCRPC Drugs Led to Longer Survival in African American Patients
The study is the first to show that treatment with abiraterone acetate/enzalutamide is associated with better survival in African American patients with mCRPC compared with Caucasians.
Sudden Cardiac Death Rates Up in Blacks vs Whites
Risk still up after adjustment for sociodemographics, comorbidity, behavioral measures of health
Barriers to Prostate Cancer Research in Black Men Identified
Mistrust, lack of knowledge, unfavorable attitudes are barriers to genomic testing, study participation
Poor Experience With PCP Linked to Hospitalization in CKD
Risk of hospitalization up for Hispanic patients with lower scores on Ambulatory Care Experiences Survey
Elevated PSA at Midlife Predicts Aggressive Prostate Cancer in Blacks
A midlife PSA value above the 90th percentile was associated with greater risk of total and aggressive prostate cancer in black men.
Next post in Prostate Cancer
